Wall Street Zen downgraded shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) from a sell rating to a strong sell rating in a research note published on Saturday morning,Wall Street Zen reports.
Several other research analysts have also issued reports on NRXP. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Tuesday, November 3rd. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, November 16th. UBS Group restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 26th. BTIG Research upped their price target on shares of NRx Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, November 11th. Finally, Wolfe Research assumed coverage on NRx Pharmaceuticals in a report on Thursday, October 15th. They set an “outperform” rating for the company. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.
View Our Latest Research Report on NRXP
NRx Pharmaceuticals Price Performance
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.16. The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.28 million. On average, equities analysts expect that NRx Pharmaceuticals will post -1.14 EPS for the current year.
Hedge Funds Weigh In On NRx Pharmaceuticals
Several large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new stake in NRx Pharmaceuticals during the 2nd quarter worth approximately $54,000. Prime Capital Investment Advisors LLC bought a new position in shares of NRx Pharmaceuticals in the third quarter valued at approximately $364,000. Marshall Wace LLP lifted its holdings in shares of NRx Pharmaceuticals by 411.4% in the third quarter. Marshall Wace LLP now owns 995,172 shares of the company’s stock valued at $2,906,000 after purchasing an additional 800,592 shares in the last quarter. B Group Inc. boosted its position in shares of NRx Pharmaceuticals by 4.5% during the third quarter. B Group Inc. now owns 4,277,200 shares of the company’s stock valued at $12,489,000 after buying an additional 185,433 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in NRx Pharmaceuticals by 30.0% during the third quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company’s stock worth $1,725,000 after buying an additional 136,350 shares in the last quarter. Institutional investors own 4.27% of the company’s stock.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.
Further Reading
- Five stocks we like better than NRx Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
